Announcement • Mar 19
CalciMedica, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Requirements
On March 13, 2026, CalciMedica, Inc. (the Company) received notice (the Notice) from The Nasdaq Stock Market LLC (Nasdaq) that the Company is not in compliance with Nasdaq's Listing Rule 5550(b)(2), as the market value of listed securities (the MVLS Requirement) for the Company's common stock had been below the minimum MVLS Requirement of $35,000,000 for the last 30 consecutive business days. Nasdaq also noted that the Company does not meet the requirements under Listing Rules 5550(b)(1) and 5550(b)(3). Under Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days following the date of the notice, or until September 9, 2026, to regain compliance. The Company may regain compliance with Nasdaq Listing Rule 5550(b) by satisfying any of the alternative continued listing standards set forth in that rule, including: (i) maintaining stockholders' equity of at least $2,500,000 under Nasdaq Listing Rule 5550(b)(1), (ii) maintaining a market value of listed securities of at least $35,000,000 under Nasdaq Listing Rule 5550(b)(2), or (iii) reporting net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years under Nasdaq Listing Rule 5550(b)(3). To the extent the Company seeks to regain compliance through the MVLS Requirement, the Company's market value of listed securities must close at $35,000,000 or more for a minimum of 10 consecutive business days during the 180-day compliance period. If the Company does not regain compliance within the compliance period, the Company expects that Nasdaq would provide notice that its securities are subject to delisting from the Nasdaq Capital Market. On March 16, 2026, the Company received a notice from Nasdaq that the Company is not in compliance with Nasdaq's Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock had been below $1.00 per share for 30 consecutive business days (the Minimum Bid Price Requirement). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days following the date of the notice, or until September 14, 2026, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the minimum bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days during this 180-day grace period. In the event the Company does not regain compliance with the Minimum Bid Price Requirement by September 14, 2026, the Company may be eligible for an additional 180 calendar day compliance period if, on the last day of the initial compliance period, the Company meets the market value of publicly held shares requirement for continued listing as well as all other standards for initial listing of its common stock on The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and provides Nasdaq written notice of its intention to cure the bid price deficiency during the second compliance period. If the Company does not indicate its intent to cure the deficiency, or if it appears to Nasdaq that it is not possible for the Company to cure the deficiency, the Company will not be eligible for the second compliance period. The notifications of noncompliance have no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market and the Company's common stock continues to trade on the Nasdaq Capital Market under the symbol CALC. The Company intends to actively monitor the Nasdaq listing requirements and will consider available options to regain compliance with the listing requirements, including such actions as a reverse stock split. There can be no assurance that the Company will be able to regain compliance with the with the applicable Nasdaq continued listing requirements or otherwise maintain compliance with the other listing requirements.
